RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $218 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams reiterates an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintains a $218 price target.
June 23, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital reiterates an Outperform rating on Sarepta Therapeutics and maintains a $218 price target.
The Outperform rating and maintained price target by RBC Capital indicate a positive outlook for Sarepta Therapeutics. This could lead to increased investor confidence and a potential short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100